Potential of Peptide Nucleic Acids in Future Therapeutic Applications

Soheila Montazersaheb1,3,*, Mohammad Saeid Hejazi2,3,†, Hojjatollah Nozad Charoudeh4,5

1 Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Anatomical Sciences Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

Peptide nucleic acids (PNA) are synthetic analog of DNA with a repeating N-(2-aminoethyl)-glycine peptide backbone connected to purine and pyrimidine nucleobases via a linker. Considering the unique properties of PNA, including resistance to enzymatic digestion, higher biostability combined with great hybridization affinity toward DNA and RNA, it has attracted great attention toward PNA-based technology as a promising approach for gene alteration. However, an important challenge in utilizing PNA is poor intracellular uptake. Therefore, some strategies have been developed to enhance the delivery of PNA in order to reach cognate site. Although PNAs primarily demonstrated to act as an antisense and antigen agents for inhibition of transcription and translation of target genes, more therapeutic applications such as splicing modulation and gene editing are also used to produce specific genome modifications. Hence, several approaches based on PNAs technology have been designed for these purposes. This review briefly presents the properties and characteristics of PNA as well as different gene modulation mechanisms. Thereafter, current status of successful therapeutic applications of PNA as gene therapeutic intervention in different research areas with special interest in medical application in particular, anti-cancer therapy are discussed. Then it focuses on possible use of PNA as anti-mir agent and PNA-based strategies against clinically important bacteria.

Introduction

Peptide nucleic acid (PNA) is a non-charged DNA-like molecule that is remarkably similar to DNA and RNA both in intramolecular spacing and geometry (Figure 1). Unlike DNA or other DNA analogues, the entire sugar-phosphodiester is replaced by a neutral charge and achiral pseudopeptide backbone to which the bases are attached via a methyl carbonyl linker. One consequence of this neutrality is the lower intrinsic electrostatic repulsion against complementary oligonucleotides, resulting in greater hybridization strengths. PNA has the capability to hybridize with high affinity and sequence specificity to complementary DNA or RNA sequence, obeying the Watson-Crick hydrogen-bonding scheme in which adenine pairs with thymine via two hydrogen bonds and cytosine forms three hydrogen bonds with guanine. PNA molecules with mixed sequences form duplexes with complementary DNA and RNA based on Watson-Crick rule. In addition, PNA can form conventional triplex structure through Hoogsteen binding in the major groove of helix of the double stranded DNA. Homo-pyrimidine PNA can form triplex invasion structure with DNA when targeting to homopurine sequence in duplex DNA (Figure 2). In this structure, one PNA strand hybridizes to its complementary DNA through Watson-Crick hydrogen bonds via antiparallel orientation, while the second PNA strand binds to the same sequence through Hoogsteen hydrogen bonds in parallel form. Because of sufficient inherently flexible polyamide structure, PNA oligomers display higher affinity and specificity when targeting DNA and RNA strands (or PNA itself) compared to natural DNA or RNA.

Figure 1. Comparison of chemical structure of PNA and DNA backbones.

*Corresponding author: Soheila Montazersaheb, Tel: +98 41 33373879, Email: montazersahebs@tbzmed.ac.ir
©2018 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
Since the introduction of PNA by Nielsen, Buchardt, Egholm and Berg (1991), it has caught attention in many fields, including molecular biology, biotechnology, biosensor systems, drug discovery, genetic diagnosis and development of gene therapeutic agents. In addition, PNA can be used as a diagnostic tool for detection of oncogenes through distinction between the wild type and the mutant target. Owing to the peptide-like chemical structure, the synthesis of PNA is similar to peptide protocols. In this way, PNA molecules are easily synthesized by well-established solid-phase manual or automated methods using either tBoc (tert-butoxycarbonyl group) or Fmoc (9-fluorenylmethoxycarbonyl group) solid phase and purification with high-performance liquid chromatography (HPLC).

**Attractive properties of PNA**

PNA possesses several peculiar and unique physicochemical properties as compared to the natural counterparts. The unnatural backbone of PNAs renders charge neutrality, eliminating electrostatic repulsion which has a negative effect on binding affinity, and causes excellent hybridization affinity to target sequence. An additional outcome is that PNAs bind independently of medium salt concentration, whereas low ionic strength reduces the stability of DNA–DNA duplexes. Also, PNAs show stability at acidic pH (pH 4.5–6.5), while DNA is prone to depurinate at lower pH. Detailed results have revealed that PNAs have higher thermal melting temperature (Tm) compared to corresponding DNA–DNA or DNA–RNA duplexes as Tm of a PNA/DNA duplex for per base pair is 1°C higher than DNA–DNA duplex.

As stated above, one crucial consequence of unnatural backbone is resistance to nuclease and protease-mediated degradation in serum and cell extracts, extending the life time of this oligomer both in vitro and in vivo. Noticeably, PNAs display very good mismatch sequence discrimination, and strong binding affinity towards DNA and RNA, making this oligonucleotide mimic an interesting third generation oligonucleotide analogue with potential therapeutic applications. PNA is capable of blocking the activity of DNA and RNA polymerases, telomerase, reverse transcriptase, endonucleases and transcription factors. Commensurate with these statements, the DNA/RNA recognition capacity has made PNA indeed a promising candidate for therapeutic application through modulation of gene expression via antigen and antisense mechanism (Table 1).

**Limitations of PNA Technology**

Despite the remarkable properties of PNA along with simplicity of synthesis and high chemical and biological stability which make PNA as a potential candidate to develop effective gene therapeutic agents, there are basic challenges still remaining for clinical application. Poor water solubility of this oligomer due to neutral character makes it to have a tendency to form globular structures. To improve the low water solubility of PNA oligomer, some modifications should be applied including addition of positively charged residues (at the terminals) and conjugation to negative charge molecules such as DNA. Another significant challenge of this hydrophilic oligomer is the poor cellular uptake. To combat limitations in crossing of PNAs and achieving sufficient intracellular delivery, several modifications can be performed to enhance cellular delivery. Without passing cell membrane, PNAs cannot interact with target sequence and therefore have no biological activity.

**PNA delivery approaches**

To make a successful PNA-based technology, there is a need to find effective methods to enhance the access of PNAs into intracellular space. A variety of methods such as spontaneous uptake in some type of nerve cells, electroporation, membrane permeabilization with streptolysin O, cationic lipids, and attachment of PNAs to cationic cell-penetrating peptides (CPPs) have been used for delivery of PNAs into the target cells. The latter approach is an extremely efficient transport carrier for moving across cell membranes. It has been shown that CPP has no significant additional cellular toxicity especially for therapeutic application. Most known examples of CPPs are positively charged amino acids including arginine and lysine which interact with glycoproteins having negative charge on the cell surface. Of note, due to guanidine moiety in arginine residue which can interact with negative groups, this amino acid is more effective than lysine. Although the mechanism of CPP-mediated delivery is still not very clear, CPPs can release their cargo into cells using two distinct mechanisms including endocytosis and direct translocation. Since PNA needs to reach the target site for modulating gene expression, the internalized cargo must be released from endosomal compartments into the cytoplasm. It is noteworthy that co-treatment with endosome disruptive agents such as chloroquine can enhance the release of entrapped cargo, and thus dramatically increase the effects of PNA-conjugates. In vivo delivery of PNA still has many limitations. As the target site of PNA molecule is located within the...
cells, so PNA must enter into the cytoplasm or nucleus with assuring circulation time and reasonable excretion until reach to the target site. As noted, PNAs are hydrophilic compound and do not cross cell membranes, therefore are excreted very rapidly with half-life of approximately less than one hour. As a result, to achieve sufficient bioavailability of PNA molecules, it must be chemically modified to assure in vivo delivery efficacy. Detailed reports revealed that conjugation to CPP peptides can improve in vivo efficacy. For instance, it has been shown that PNA conjugated to oligoarginine has moderate activity in muscles in the mdx mice. Notably, nanoparticle PNA-based strategies can be used for efficient delivery of PNA to target sites.\textsuperscript{18,19}

**Advantage and disadvantage of PNA in gene-based therapy**

Gene therapy uses foreign genes or short oligonucleotide sequences as therapeutic agents. Several approaches can be used for correcting of defect genes such as addition of functional alleles and correction via homologous recombination, introduction of suicide genes and produgs and inhibition of gene expression through synthetic oligonucleotides. There is particular interest in using oligonucleotides due to specificity to cognate site and non viral-based strategies. In conventional gene therapy, viral vectors are often used for gene delivery that may cause some risks including, stimulation of immune reaction and more importantly insertion of oncogene.\textsuperscript{20}

PNAs are more efficient in terms of gene modulation, compared to traditional oligonucleotides such as phosphorothioate. For instance, one study showed that higher concentration of PNA is required for inhibition of gene expression than propyne-phosphorothioate oligonucleotides. Even supposing that higher concentrations of PNA is necessary to obtain reasonable antisense effects, the unique properties of PNA such as resistance to enzymatic digestion, higher stability, and specificity of PNA molecule to target sequence make it a powerful choice for gene therapy.\textsuperscript{1}

**Gene modulation mechanisms of PNA molecules**

**Antigene applications of PNA**

PNAs have the ability to hybridize to complementary sequences at the DNA and interfering with the transcription of the target gene and as a consequence, reducing the mRNA level (Figure 3). In fact, PNA is capable of arresting transcriptional processes by virtue of its ability to form different complexes with dsDNA such as a stable triplex structure, strand invasion or strand displacement complexes leading to structural hindrance of RNA polymerase, as depicted in Figure 2.\textsuperscript{21} Triplex-forming PNA can hamper the initiation of transcription by preventing duplex DNA unwinding or inhibition of transcription factor binding to the promoter region of target genes. Moreover, triplex-invasion structures within the transcribed region on the template strand can block the elongation of RNA polymerase along with the appearance of truncated RNA transcripts, inducing transcriptional inhibition.\textsuperscript{22} Targeting chromosomal DNA is less effective due to difficult access to target sequence under physiological conditions. For instance, the presence of cations has potential to stabilize the DNA double strands, resulting in the reduction of helix invasion by the PNA. On the other hand, specific gene modulation via antigen mechanism is advantageous over antisense approaches, in that one (or two) copy of target sequence is evoked compared to many targets of mRNAs present in the cell.\textsuperscript{23}

**Antisense applications of PNA**

In the case of RNA interference, PNA molecules mediate inhibitory effects on translational process via steric blocking mechanisms. Since PNA oligomers neither activate ribonuclease H (RNase H) nor enter RNA-induced silencing complexes (RISC) (Figure 4A), thus, antisense role of PNA may rely on mechanistic interference via different mechanisms rather than degradation of mRNA. PNAs hamper translation process through RNA transport to cytoplasm, elongation process, and translation initiation such as ribosome assembly.\textsuperscript{24} Of note, inhibitory effects

---

**Figure 3.** Schematic illustration of PNA-based strategy as antigene and antisense agents. Antigene PNA binds to complementary sequence in DNA and inhibits transcriptional process while antisense PNA hybridize to target sequence in mRNA and prevent translation procedure.
depend on hybridization strength and good accessible sequence on the mRNA molecule. Interestingly, it has been observed that duplex-forming PNAs with mixed sequence have the highest potency when targeted to AUG regions (translational start codon) or 5’terminus of mRNA (5’UTR), where ribosomal assembly occurs. Alternatively, homopyrimidine triplex-forming PNAs inhibit elongation process, leading to truncated products, whereas as noted above, duplex PNA can efficiently prevent the ribosomal assembly rather than arresting elongation (Figure 4B). Detailed data demonstrated that complete blockage of translation can be efficiently achieved by applying two or more duplex-forming PNAs. Overall, a crucial rule is considering the 5’UTR and AUG as suitable regions to obtain good antisense activity for duplex forming PNA.25,26 Certainly, ribosomes of eukaryotic cells recognize the translation initiation codon through scanning the mRNA sequence from the 5’-cap site to AUG codon. During the scanning process and before recognition of start codon, the assembly of ribosome has not completely occurred and is most likely not connected with the mRNA. As a result, the translation machinery is a good target to block due to accessibility of PNAs to cognate regions.

**Figure 4.** Some mechanisms involved in modulation of gene suppression: A) Antisense activity and RNA interference mechanisms. B) Inhibitory effect of antisense PNA via different approaches. PNAs have the ability to target AUG regions (translational start codon) or 5’UTR, where the starting point of ribosomal assembly occurs and block process, whereas triplex forming PNAs can inhibit elongation process via targeting to coding region. ASO: antisense oligonucleotide.

**Modulation of splicing with PNA-based strategy**

Interfering the splicing pattern is another important application of antisense PNAs, targeting and blocking specific intron-exon splice junctions within the pre-mRNA molecule. Upon targeting a PNA molecule to intron-exon junction sites, splicing machinery (spliceosome) either skips one exon (or more) or may retains intron sequence. As depicted in Figure 5, intron retention leads to the production of nonfunctional mRNA containing an intron, which is susceptible to destabilization. On the other hand, exon skipping produces an alternative protein similar to alternative splicing procedure. Since several diseases result from shifting in the splicing patterns of pre-mRNA, so interference with splicing procedure may create novel possibilities for drug development.27 The process of pre-mRNA splicing is carried out by a very large ribonucleoprotein (RNP) complex through the removal of the intronic sequences accompanied by joining the exons at intron-exon junctions. This process is mediated by directing the spliceosome to correct splice sites at the intron-exon junctions including the 5’ and 3’ junction sites and the branch point. Employment of PNA-based technology can block correct splicing sites, which is critical for splicing mechanism.28 Alternative splicing can produce multiple mRNA isoforms from one gene and thus, leads to the generation of proteins with different functions. Many studies demonstrated that alternative splicing can be used to alter gene production based on physiological condition. For instance; human genes containing introns can undergo alternative splicing to adjust the desired
output.\(^{29}\) In addition, numerous therapeutic approaches are available to correct aberrant splicing in many disorders. Altering the splicing pattern of pre-mRNA can be done by antisense oligonucleotides in various disorder-related genes such as tau, c-myc, IL-5R, bcl-x, dystrophin, and β-globin for obtaining therapeutically favorable results.\(^{30,31}\) Overall, PNA targeting pre-mRNA sequences can efficiently modulate splicing process to obtain desirable outcome.\(^{32,33}\)

**PNA-based Gene Editing Approach**

Triplex-forming PNAs are effective tools to induce homologous recombination in the presence of donor DNA. For achieving this process, two PNA molecules are attached together by a linker, forming a bis-PNA. One strand of bis-PNA binds in the anti-parallel orientation based on Watson-Crick rule, and the other strand is attached via Hoogsteen bond in the parallel direction to dsDNA, making triplex formation. This structure leads to distortion of DNA helical, which has the ability to provoke DNA repair system, and results in the recombination of “donor” DNA into the desired target near binding site of PNA (Figure 6). This technology for *in vivo* site-specific gene modification is a novel approach to treat human disease. Other gene editing technologies are based on exogenous nucleases activity such as CRISPR/Cas, they may possibly create breaks in dsDNA, whilst PNA-mediated gene editing relies on repair pathways with high fidelity, thus reducing the error of end-joining which can cause additional mutations.\(^{14}\)

**PNA as a potential therapeutic agent for cancer therapy**

Cancer is a major health problem in the world and is recognized mainly as genetic disease resulting from mutations of oncogene and tumor suppressor genes. The goal of cancer therapy is to find and develop novel strategies for modulating the expression of cancer-related genes using selective anticancer agents with no cytotoxic effects as observed in conventional chemotherapy.\(^{34}\) It has been shown that antigene and antisense strategies can be used to modulate transcription and translation of tumor genes. Moreover, numerous *
vitra and in vivo experiments have already demonstrated the ability of PNA in controlling the dynamics of tumor gene expression. In accordance with a plethora of experiments, telomerase is found overexpressed in approximately 90% of human cancers, thereby being responsible for the immortalized cell phenotype. Of note, the modulation of this enzyme can be touted as an attractive target for cancer therapy. Besides, PNA per se has potential to hybridize to the RNA template region of telomerase and inhibit the catalytic activity of the enzyme. Overall, these results point out PNAs may be valuable tools for target-directed anticancer agents.

Bcl-2 is a 26-kD protein, which has a key role in the dynamic of apoptosis. Overexpression of Bcl-2 correlates with prolonged survival of cells, tumor development, poor prognosis and resistance to anticancer therapies. With this background, the control of bcl-2 expression is an interesting approach in cancer therapy. They examined various PNAs targeted to different regions of mRNA sequences. In vitro investigations further showed that the synthesis of bcl-2 protein was blocked through PNA targeted to 5´UTR and the AUG codon of human B-cell lymphoma in a dose-dependent pattern. Moreover, the combined use of both PNAs produced complete inhibition, whereas partial translation inhibition was seen with single PNA usage. Also, a triplex forming bis-PNA was capable of binding to the template DNA strand of the bcl-2 gene and specifically suppressed the transcription of the gene with the presence of truncated product. Overall, PNA-based approach was able to selectively manipulate both translation and transcription of bcl-2 gene in vitro.

Chronic myeloid leukemia (CML) is a malignancy, resulted from translocation of chromosomes 9q and 22q, the Philadelphia chromosome (Ph), and generate the bcr/abl oncogene. This gene produces a protein (p210BCR/ABL) with high tyrosine kinase activity, leading to cell proliferation and malignant behavior. Thus, the unique sequence of bcr/abl is an attractive target for antisense therapy in CML disease. The incubation of CML cells with13mer antisense PNA targeted to b2a2 junction in mRNA contributed to 35% decline in the level of p210BCR/ABL protein compared to control group. Also, anti-b2a2 PNAs have a strong antiproliferative effect in a dose dependent manner from 26% to 50% at 5 and 10 µM, respectively, displaying cell growth arrest. Acute promyelocytic leukemia (APL) is characterized by expression of the promyelocytic leukemia/retinoic acid receptor alpha gene (PML/RARα/PR). Fusion protein PML/RARα exists in all cases of APL and is generated by translocation of t (15; 17) chromosome. In this cancer model, the possibility of translation inhibition of the fused oncogene was tested by three different antisense PNAs targeting to first AUG start codon and second AUG and 5´UTR region of the fused oncogene sequence. Data showed PNAs directed against 5´UTR had the highest inhibitory activity compared to other ones. In fact, the limited effect of blocking was observed when PNAs used separately and a complete inhibition was achieved by the combination of these PNAs. Myc proteins play a key role in cancer. Overexpression of this protein is often correlated with DNA hypermethylation, higher cell growth rate, genomic instability and immortalization which lead to aggressive behavior of tumors. Commensurate with these statements, MYCN gene can be considered as an important target for cancer therapy with novel therapeutic inhibitors such as PNA to manage proliferation and apoptosis pathways and reduce the malignant behavior of the tumor. The possibility of PNA-based strategy for inhibition of MYCN transcription was previously examined by Tonelli and colleagues. They used an antigen PNA linked with nuclear localization signal peptide (NLS) targeted against a unique sequence of MYCN DNA (antisense DNA strand of exon 2) in six different cell lines of human neuroblastoma. The in vitro data showed a significant inhibition of MYCN expression by the antigen PNA in MYCN-amplified and MYCN-unamplified/low-expressed cell lines, leading to a reduction in cell proliferation rate, although no decrease was seen in MYCN-unamplified/unexpressed cell lines. Compared with an antisense PNA, the inhibitory effect of the antigen PNA on MYCN gene expression showed stronger and longer inhibitory effect.

Burkitt’s Lymphoma (BL) cell is characterized by upregulation of the c-myc oncogene due to translocation of chromosome 8 to chromosome 14, proximal to Eµ enhancer within the Ig heavy chain locus that can induce transformed features. Therfore downregulation of translocated c-myc with a specific PNA, can reduce transformed properties in BL. Given that translocated c-myc is under Eµ enhancer control, PNAEµ targeting to enhancer sequence seem to be a potential therapeutic agent. In a preliminary experiment, evaluation of pharmacokinetic parameters for PNA to an in vivo model system in severe combined immunodeficiency mice (SCID) demonstrated that after administration of PNA, it can persist intact in an in vivo system for prolonged time about 600 minutes. In this regard, PNA targeted to the Eµ enhancer region located on chromosome 14 caused selective downregulation of only translocated c-myc not the normal allele. Furthermore, using mice inoculated with the BL system demonstrated the potential capacity of PNAs to specifically and selectively block BL cells expansion and downregulation of c-myc expression.

In addition, in a study, Cutrona and co-workers showed the effect of an anti-gene anti-myc PNA conjugated to a NLS in (BL) cell line. The authors used a 17-mer anti-myc PNA targeted to a unique sequence at the beginning of the second exon of the gene. The results indicated that PNA with 10 mM concentration achieved maximum inhibition of MYC expression (75%) and approximately (25%) reduction in cell viability, demonstrating that PNA specifically down-regulates the expression of c-myc via binding to the double-stranded DNA in vitro.
consequence, PNAs are capable of inhibiting transcription of the targeted gene \textit{in vitro} as well as \textit{in vivo}, offering new specific therapeutic approaches to cure neoplasia.\textsuperscript{45}

**PNA as a splicing modulator in clinically relevant approaches**

The erbB2 gene is amplified in approximately 20–35\% of human breast cancers and other cancer types. Several studies indicated that overexpression of this gene is accompanied by the higher aggressiveness of the tumor and more importantly development of resistance to anti-estrogen treatment and chemotherapeutic strategies.\textsuperscript{46} It has been shown that the application of antisense technology may be a useful approach towards treatment of breast cancers by targeting the translation start codon or the 3'-UTR region of the Her-2 mRNA to suppress the expression of Her-2 oncoprotein.\textsuperscript{47} In line with this hypothesis, Nielsen et al. examined several antisense PNA oligomers targeted to intron-exon junction sites to interfere with correct splicing of erbB-2 pre-mRNA in two cancer cell lines. Since exon 19 codes ATP catalytic domain of Her-2, PNA oligomers are targeted to the 5' exon-intron junction site to induce skipping of exon 19 which harbors many of the Her-2 cancer-related mutations. Considering the flexibility of the splicing machinery,\textsuperscript{48} obstruction of the 5' splice site could shift the spliceosome to another available splice site such as the 5' splice site of exon 20. Although the mechanism of skipping by PNA is not clear, it can be due to steric hindrance of pre-mRNA along with misleading of spliceosome through obstructing the correct splice site. The result demonstrated splicing redirection of Her-2 pre-mRNA by full-matched antisense PNA via skipping of erbB-2 exon 19. PNA-mediated activity can potentially be developed as anticancer strategies.\textsuperscript{59}

The mdm2 oncogene encodes a nuclear phosphoprotein that inactivates the function of the p53 tumor suppressor protein. This oncogene is overexpressed in a wide variety of cancers.\textsuperscript{50} In cancer therapy, mdm2 down-regulation is a promising strategy which might lead to the induction of p53. In agreement with this claim, Nielsen et al. obtained inhibition of mdm2 mRNA translation by PNA targeting to initiation site (AUG), whereby p53 levels increased.\textsuperscript{51} Therefore, the mdm2 oncogene is an interesting antisense target for developing novel therapeutic agents and anticancer drugs. As mentioned above, PNA molecules were found to have a potent capability to target intron-exon junction sites. Again, Nielsen et al. designed several PNA molecules to down-regulate full-length mRNA of mdm2 or alter splice variants in human JAR cells through modulating splicing patterns. PNA oligomers tested toward the 5' or 3' splice sites in intron2 of mdm2 pre-mRNA inhibit splicing by generating a larger mRNA having retained intron 2. Among the PNAs, the most efficient is a complement to 4 bases in intron2 and 11 bases in exon3. Interestingly, another PNA which targets the 3' splice site of intron3 and is complementary to 4 bases in intron3 and 11 bases in exon4, exhibited both exon skipping as well as intron retention.\textsuperscript{52}

Duchenne muscular dystrophy (DMD) is a lethal disease caused by point mutations in the dystrophin gene due to stop codon in exon 23 out of 79 exons. This early termination leads to complete loss of the functional muscle protein dystrophin throughout the body, which induces muscle complications. Although two FDA-approved drugs are in clinical use to treat DMD patents, exon-skipping antisense oligonucleotide is still a promising approach in restoring reading frame and functional dystrophin protein. Preclinical studies revealed that PNAs are very promising method to induce splice correction by exon skipping in pre-mRNA of the DMD in mdx mice through intramuscular and systemic PNA delivery. PNA target to the intron22/exon23 junction site can induce skipping of exon 23 and produce a shortened protein still in reading frame shift with adequate activity to restore muscle function in a mouse (mdx) model. Also, it has been shown that single intramuscular administration of PNA could efficiently trigger exon-skipping, inducing dystrophin expression along with significant numbers of dystrophin-positive fibers in muscles in the mdx muscular dystrophy mouse model.\textsuperscript{53} In parallel, identically designed experiment, intravenously repeated injections of high dose of PNA in mdx mice, elicited exon skipping accompanied by systemic therapeutic level of dystrophin expression and functional improvement with phenotypic rescue of mdx mice without major detectable toxicity. Based on the findings, PNA-base strategy is indeed a potent and promising applicable approach for DMD exon-skipping therapeutics, achieving restoration of functional dystrophin protein.\textsuperscript{54}

**Therapeutic approach of PNA as a gene editing agent**

Available treatment for monogenic blood disorders such as sickle cell anemia and thalassemia is allogenic transplantation. However, limited accessibility of histocompatible donors along with associated side effects offers alternative strategies such as gene-targeted oligonucleotides with therapeutic potential.\textsuperscript{55} In support of this statement, Rogers and his colleague tested the possibility of PNA as a gene editing agent in hematopoietic progenitor cells in a mice model to stimulate site-specific mutations while retaining differentiation capability of Hematopoietic stem cell (HSC). For systemic administration, PNA was linked to transport peptide Antp to target gene in murine. Intraperitoneally injected PNAs were targeted to reporter gene (supFG1) which was chromosomally integrated in transgenic mice. Results showed mutations in the supFG1 gene and higher mutation frequencies were observed within the PNA-binding site, demonstrating that HSCs can be chromosomally changed by systemically administered PNA. It should be addressed that gene modification was observed in all the hematopoietic progenitors, including erythroid, myeloid and lymphoid cell lineages. These findings clearly
revealed the clinical importance of in vivo HSCs gene therapy with a PNA-mediated approach in a stem cell population. This approach can be a new applicable therapeutic agent providing gene therapy in systemic diseases that cannot be manipulated outside the body.\textsuperscript{56} As mentioned above, triplex-forming PNAS can correct the mutant gene by engaging the cell’s own DNA repair machinery via triggering recombination in the presence of a single stranded DNA template.\textsuperscript{57} In an analogous study, gene-targeting strategy through intravenous injection of biodegradable nanoparticle containing triplex forming PNA (PNA-DNA-PNA) plus donor DNAs were used to edit hematopoietic stem cells in HSC engrafted mice. The results demonstrated modification of the human CCR5 gene in multiple organs in the mice, which is clinically relevant to human cells. To demonstrate the versatility of this approach, they administered nanoparticles carrying triplex forming PNAS which were targeted to β-globin, a gene associated with thalassemia disease. Analysis showed single base-pair modification in the second intron of the β-globin gene in a transgenic mice.\textsuperscript{58} These findings are in line with in vitro study in which triplex forming PNAS could modify the human CCR5 gene, thus producing human immunodeficiency virus (HIV) resistant cells, as well as correcting single base-pair mutation at the intron of the β-globin gene, a common site of thalassemia-associated mutation.

Since PNAS cannot readily cross the cell membrane and are excreted within 10–30 min after intravenous or intraperitoneal administration, hence, a delivery tool is required to access the target for in vivo gene editing. It has been shown that PNA and donor DNA could be efficiently encapsulated in poly (lactic-co-glycolic acid) (PLGA) nanoparticle, a FDA-approved polymer for in vivo drug delivery. This carrier can lead to higher efficiency in terms of gene editing both in vitro and in vivo.\textsuperscript{59} Bahal and McNeer reported related results by injection of nanoparticles containing next generation PNA chemistry (γPNAs) and donor DNAs targeted haematopoietic stem cells (HSCs) in a mouse model of human b-thalassemia. They observed in vivo gene editing of a b-thalassemia mutation in transgenic mice by simple intravenous injection of nanoparticles containing γPNA/donor DNA. In this way, the phenotype of the disease was ameliorated via elevation of blood haemoglobin levels, reduction of reticulocytosis, and reversal of splenomegaly.\textsuperscript{60} Taken together, these findings encourage the development of in vivo gene editing through PNA mediated approaches as a novel therapeutic strategy for the treatment of inherited human disorders. In a similar research, two PNAS form a bis-PNA and bind to double stranded DNA forming triplex structure by Watson-crick and hoogsteen bond. In this process, γ position of regular PNA is attached to a mini-polyethylene glycol chain to enhance solubility and binding efficacy for the DNA target. Nanoparticles containing γPNAs and 60 bp donor DNAs were administered intravenously and intra amniotically to fetal mouse tissues in order to correct IVS2-654 mutation in the β-globin gene in a mouse model of human β-thalassemia. Obtained result revealed that this strategy can cure anemia in thalassemic mice. The result revealed that PNA-mediated gene editing is an attractive method of gene editing during pregnancy, providing higher advantage compared to after birth therapy due to accessibility to progenitor cells (HSCs), which can result in propagation of the corrected gene in all progeny cells.\textsuperscript{61}

**Therapeutic Application of PNAs as Anti-miR agent**

MicroRNAs (miRNAs) have important regulatory role in gene expression at post transcriptional stage. Additionally, upregulation of miRNAs expression is seen in several diseases remarkably in cancer, therefore they can be considered as important therapeutic targets.\textsuperscript{62} Notably, anti-miR PNAs can bind miR and inhibit interaction with the RISC complex through steric hindrance, thus reducing miR expression.\textsuperscript{63} It has been shown that PNAs have the capability to efficiently inhibit miR-155 which is expressed in the haematopoietic system in primary B cells as well as in mice model of lymphoma.\textsuperscript{64,65} Additionally, it has been reported that PNA can be used as an inhibitor of miR-509-3p, which is cystic fibrosis transmembrane regulating miRNA.\textsuperscript{66} Moreover, various MicroRNAs such as miR-210 are considerably upregulated in response to hypoxia condition, which is common in tumors development. MiR-210 may play a key role in survival and proliferation of tumor cells; it can be a good target for anti-cancer therapy. In a recently published study, γPNAs was used as a modified version of PNA to overcome limitations such as insolubility and tendency of globular formation. A regular PNA, a gamma PNA, and a control (mismatched) of 22 mer PNA were designed to target miR-210 in tumor Hela cell which grows as xenografts in immune-deficient nude mice using nanoparticle as a delivery system. Histopathological evidence showed that gamma PNAs targeted to miR-210, significantly suppressed tumor growth as well as increased the rate of apoptosis, compared to a regular PNA. Furthermore, expression of miR-210 is evaluated by RT-PCR in RNA extracted from the Hela tumor cells. There was a reduction in miR-210 expression levels compared to the control group. Under hypoxic condition, increase level of miR-210 is accompanied by suppression of ISCU protein which is downstream target of miR-210. Thus upon inhibition of miR-210, expression of ISCU is increased. Overall, PNA can inhibit microRNAs, offering novel approach in cancer therapy.\textsuperscript{67}

**Application of PNAs as anti-infective agent**

In recent years, the rate of multi-drug resistant bacteria has increased, so it is required to treat these bacteria via developing novel drugs. Since PNA can inhibit gene expression of target gene, it can be used as antibacterial
compounds to treat patients suffering from multidrug resistant bacteria. It has been reported that antisense PNA can target a variety of genes in *Pseudomonas aeruginosa*, the most clinically common and is resistant to a wide range of antibiotics. Recent findings also addressed that antisense PNAs have potential to manipulate gene expression in *Plasmodium falciparum* through down regulation of an essential gene (PfSec13) which is responsible for viability in parasite. This alternative approach can be used to develop a novel and specific antimalarial drugs. Of note, PNAs have no antibacterial activity without sequence-based homology with target site. PNA can selectively bind to the conserved sequence in variety of bacterial genus and inhibit growth in broad-spectrum of bacteria. It has been revealed that PNA targeted to translation initiation region of specific genes including *Bacillus subtilis* (gram-positive bacteria) and *Escherichia coli*, *Klebsiella pneumoniae* and *Salmonella Typhimurium* (gram negative bacteria) in a mixed culture, selectively kills bacteria, so these findings open a novel opportunities for designing new therapeutic intervention for the treatment of pathogen bacteria.

### Conclusion

Since the invention of PNA, several applications have been developed based on the unique properties of this oligomer; in particular, exploiting alteration of gene expression with focus on the antisense and antigenic activity of PNA. Much attention has recently been given for possible clinical applications of PNAs in combination with drugs which are used in the clinic in cancer therapy based on *in vivo* experimental systems and clinical trials. However, in practice, great consideration is still needed in terms of *in vivo* administration such as immunogenicity, biodistribution, and other problems related to drug development.

### Acknowledgments

This review is a part of Ph.D thesis of Soheila Montazerasheb (Thesis No. : 102) at Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. The authors would like to acknowledge Prof. Peter Nielsen (University of Copenhagen, Denmark) for helpful comments on the manuscript.

### Ethical Issues

Not applicable.

### Table 1. Several examples of PNA-mediated gene therapy

| Antigene | Target site | In vivo / in vitro | Disorder | Observed Effects | Ref. |
|----------|-------------|--------------------|----------|------------------|-----|
| PNA      | COL1A1 gene | Normal human fibroblast cell line | Fibroproliferative Disorders | Reduction of mRNA level | 72  |
| Antigene PNA | RAD51 gene | Human MIM cell line H929 & a SCID-rab mouse model | Multiple Myeloma (MM) | Inhibition of RAD51 expression | 73  |
| Antigene PNA | MYCN gene | Rhabdomyosarcoma cell line | Rhabdomyosarcoma | Reduction of MYCN expression | 74  |
| Antisense PNA | COL7A1 gene | in vitro/ Primary adult fibroblast cultures | Dominant Dystrophic Epidermolysis Bullosa | Inhibition of the transcription of a mutant COL7A1 | 75  |
| Antisense PNA | miR-155 | Mice | Lymphomas | Inhibition of oncomiR-155 | 76  |
| Antisense PNA | miR-221 | Human breast cancer MCF-7 & MDA-MB-231 cell lines | Breast Tumors | Inhibition of onco miR-221 | 77  |
| Antisense PNA | miR-509-3p | A549 cell lines | Cystic Fibrosis | Inhibition of miR-509-3p | 78  |
| Antisense PNA | Targeting LTR Direct Repeats of HBV RNA Intron containing Mutation(the IVS2-654) | HEPG2 cell line & an acute hepatitis B mouse model | Hepatitis B | Decline in HBV DNA | 79  |
| yPNA and donor DNA | | in vivo (β-globin/eGFP transgenic mouse) | β-thalassaemia | Induce DNA repair in mutated gene | 79  |
| Antigene | Dystrophin Gene in Muscle Stem Cells | ex vivo/ in mdx mice, a mouse model of DMD | Duchenne muscular dystrophy | Permanently correct single-point mutations at the genomic level in stem cells | 80  |

### Conflict of Interest

There is no conflict of interest in this study.

### References

1. Dean DA. Peptide nucleic acids: Versatile tools for gene therapy strategies. *Adv Drug Deliv Rev* 2000;44(2-3):81-95. doi: 10.1016/S0169-409X(00)00087-9
2. Pellestor F, Paulasova P. The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytotgenetics. *Eur J Hum Genet* 2004;12(9):694-700. doi: 10.1038/sj.ejhg.5201226
3. Nielsen PE. Peptide nucleic acids (PNA) in chemical biology and drug discovery. *Chem Biodivers* 2010;7(4):786-804. doi: 10.1002/ebvd.201000005
4. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. *Science* 1991;254(5037):1497-500. doi: 10.1126/science.1962210
5. Raof JB, Ojani R, Golabi SM, Hamidi-Asl E, Hejazi MS. Preparation of an electrochemical PNA biosensor for detection of target DNA sequence and...
single nucleotide mutation on p53 tumor suppressor gene corresponding oligonucleotide. Sens Actuators B Chem 2011;157(1):195-201. doi: 10.1016/j.snb.2011.03.049

6. Sharma C, Awasthi SK. Versatility of peptide nucleic acids (PNAs): Role in chemical biology, drug discovery, and origins of life. Chem Biol Drug Des 2017;89(1):16-37. doi: 10.1111/cbdd.12833

7. Metaferia B, Wei JS, Song YK, Evangelista J, Aschenbach K, Johansson P, et al. Development of peptide nucleic acid probes for detection of the HER2 oncogene. PLoS One 2013;8(4):e58870. doi: 10.1371/journal.pone.0058870

8. Braasch DA, Nulf CJ, Corey DR. Synthesis and purification of peptide nucleic acids. Curr Protoc Nucleic Acid Chem 2002;9(1):4.11.1-4. 8. doi: 10.1002/0471142700.uc04i1s09

9. Hejazi MS, Pournaghi-Azar MH, Alipour E, Abdolhainia ED, Arami S, Navvah H. Development of a novel electrochemical biosensor for detection and discrimination of DNA sequence and single base mutation in dsDNA samples based on PNA-dsDNA hybridization-a new platform technology. Electroanalysis 2011;23(2):503-11. doi: 10.1002/ealan.201000413

10. Ahour F, Pournaghi-Azar MH, Alipour E, Hejazi MS. Detection and discrimination of recombinant plasmid encoding hepatitis C virus core/E1 gene based on PNA and double-stranded DNA hybridization. Biosens Bioelectron 2013:45:287-91. doi: 10.1016/j.bios.2013.01.063

11. Siddiquee S, Rovina K, Azriah A. A review of peptide nucleic acid. Adv Tech Bio Med 2015;3(2). doi: 10.4172/2379-1764.1000131

12. Nielsen PE. Modulating gene function with peptide nucleic acids (PNA). In: Crooke ST, editor. Antisense drug technology. Taylor & Francis; 2008. P. 507-18.

13. Nielsen PE. Peptide nucleic acid: A versatile tool in genetic diagnostics and molecular biology. Curr Opin Biotechnol 2001;12(1):16-20. doi: 10.1016/S0958-1669(00)00170-1

14. Quijano E, Bahal R, Ricciardi A, Saltzman WM, Glazer PM. Therapeutic peptide nucleic acids: Principles, limitations, and opportunities. Yale J Biol Med 2017;90(4):583-98.

15. Nielsen PE. Addressing the challenges of cellular delivery and bioavailability of peptide nucleic acids (PNA). Q Rev Biophys 2005;38(4):345-50. doi: 10.1017/S0033583506004148

16. Shiraishi T, Nielsen PE. Enhanced delivery of cell-penetrating peptide-nucleic acid conjugates by endosomal disruption. Nat Protoc 2006;1(2):633-6. doi: 10.1038/nprot.2006.92

17. Sait Hassane F, Saleh AF, Abes R, Gait MJ, Lebleu B. Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010;67(5):715-26. doi: 10.1007/s00018-009-0186-0

18. Nielsen PE, Shiraishi T. Peptide nucleic acid (PNA) cell penetrating peptide (CPP) conjugates as carriers for cellular delivery of antisense oligomers. Artif DNA PNA XNA 2011;2(3):90-9. doi: 10.4161/adna.18739

19. Margus H, Padari K, Pooga M. Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 2012;20(3):525-33. doi: 10.1038/mt.2011.284

20. Gonçalves GAR, Paiva RMA. Gene therapy: Advances, challenges and perspectives. Einstein (Sao Paulo) 2017;15(3):369-75. doi: 10.1590/S1679-45082017RB4024

21. Shakeel S, Karim S, Ali A. Peptide nucleic acid (PNA)—a review. J Chem Technol Biotechnol 2006;81(6):892-9. doi: 10.1002/jctb.1505

22. Hu J, Corey DR. Inhibiting gene expression with peptide nucleic acid (PNA)—peptide conjugates that target chromosomal DNA. Biochemistry 2007;46(25):7581-9. doi: 10.1021/bi700230a

23. Janowski BA, Kahiatsu K, Huffman KE, Schwartz JC, Ram R, Hardy D, et al. Inhibiting transcription of chromosomal DNA with antigen peptide nucleic acids. Nat Chem Biol 2005;1(4):210-5. doi: 10.1038/nchembio724

24. Zaffaroni N, Villa R, Folini M. Therapeutic uses of peptide nucleic acids (PNA) in oncology. In: Janson CG, During MJ, editors. Peptide nucleic acids, morpholinos and related antisense biomolecules. Springer; 2006. P. 171-80.

25. Järver P, Coursindel T, Andaloussi SE, Godfrey C, Wood MJ, Gait MJ. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids 2012;1:e27. doi: 10.1038/mt.2012.18

26. Nielsen E. RNA targeting using peptide nucleic acid. In: Erdmann V, Barciszewski J, Brosius J, editors. RNA towards medicine. Berlin: Springer; 2006. P. 395-403.

27. Nielsen PE. Gene targeting using peptide nucleic acid. In: Herdevijn P, editor. Oligonucleotide synthesis. New Jersey: Humana Press; 2005. P. 343-58.

28. Wahl MC, Will CL, Lührmann R. The spliceosome: Design principles of a dynamic RNP machine. Cell 2009;136(4):701-18. doi: 10.1016/j.cell.2009.02.009

29. Szani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003;112(4):481-6. doi: 10.1172/JCI19547

30. Yang SP, Song ST, Song HF. Advancements of antisense oligonucleotides in treatment of breast cancer. Acta Pharmacol Sin 2003;24(4):289-95.

31. Aartsma-Rus A, Van Ommen GJ. Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA 2007;13(10):1609-24. doi: 10.1261/rna.653607

32. Garcia-Blanco MA. Alternative splicing: Therapeutic target and tool. Prog Mol Subcell Biol 2006;44:47-64.
PNA as a therapeutic agent

33. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. *Nat Biotechnol* 2004;22(5):535-46. doi: 10.1038/nbt964

34. Mologni L, Gambacorti-Passerini C. PNAs as novel cancer therapeutics. *Lett Pept Sci* 2003;10(3-4):297-308. doi: 10.1007/bf02484565

35. Nielsen PE. Gene targeting and expression modulation by peptide nucleic acids (PNA). *Curr Pharm Des* 2010;16(28):3118-23. doi: 10.2174/138161210793292546

36. Mologni L, Nielsen PE, Gambacorti-Passerini C. In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. *Biochem Biophys Res Commun* 1999;264(2):537-43. doi: 10.1006/bbrc.1999.1548

37. Rapozzi V, Burn M, Cogoi S, van der Marel GA, van Boom JH, Quadrifoglio F, et al. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. *Nucleic Acids Res* 2002;30(17):3712-21. doi: 10.1093/nar/gkf451

38. Mologni L, le Coutre P, Nielsen PE, Gambacorti-Passerini C. Additive antisense effects of different PNAs on the in vitro translation of the PML/RARa gene. *Nucleic Acids Res* 1998;26(8):1934-8. doi: 10.1093/nar/26.8.1934

39. Vita M, Henrikkson M. The Myc oncoprotein as a therapeutic target for human cancer. *Semin Cancer Biol* 2006;16(4):318-30. doi: 10.1016/j.semcancer.2006.07.015

40. Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. *Cell* 2013;152(6):1237-51. doi: 10.1016/j.cell.2013.02.014

41. Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: A children’s oncology group study. *Br J Cancer* 2015;113(1):57-63. doi: 10.1038/bjc.2015.188

42. Tonelli R, Purgato S, Camerini C, Fronza R, Bologna F, Alboresi S, et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. *Mol Cancer Ther* 2005;4(5):779-86. doi: 10.1158/1535-7163.mct-04-0213

43. Boffa LC, Cutrona G, Cilli M, Mariani MR, Matis S, Pastorino M, et al. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: Pharmacokinetics in an animal model of human burkitt’s lymphoma. *Oligonucleotides* 2005;15(2):85-93. doi: 10.1081/oli.200051585

44. Boffa LC, Cutrona G, Cilli M, Matis S, Damonte G, Mariani MR, et al. Inhibition of burkitt’s lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. *Cancer gene ther* 2007;14(2):220-6. doi: 10.1038/sj.cgt.7701002

45. Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, Ferrarini M, et al. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. *Nat Biotechnol* 2000;18(3):300-3. doi: 10.1038/73745

46. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. *Biochem Biophys Res Commun* 2004;319(1):1-11. doi: 10.1016/j.bbrc.2004.04.150

47. Roh H, Pippin J, Dreibin JA. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. *Cancer Res* 2000;60(3):560-5.

48. Mercatante DR, Kole R. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: Effects on gene expression. *Biochim Biophys Acta* 2002;1587(2-3):126-32. doi: 10.1016/S0925-4439(02)00705-3

49. Pankratova S, Nielsen BN, Shiraishi T, Nielsen PE. PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: Specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. *Int J Oncol* 2010;36(1):29-38. doi: 10.3892/ijo_0000472

50. Zhao Y, Yu H, Wu W. The regulation of MDM2 oncogene and its impact on human cancers. *Acta Biochim Biophys Sin (Shanghai)* 2014;46(3):180-9. doi: 10.1093/abbs/gmt147

51. Shiraishi T, Nielsen PE. Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminooacidine-PNA (peptide nucleic acid) conjugates. *Nucleic Acids Res* 2004;32(16):4893-902. doi: 10.1093/nar/gkh820

52. Shiraishi T, Eyustkaró J, Nielsen PE. Modulation of mdm2 pre-mRNA splicing by 9-aminoeacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions. *BMC Cancer* 2010;10:342. doi: 10.1186/1471-2407-10-342

53. Yin H, Lu Q, Wood M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. *Mol Ther* 2008;16(1):38-45. doi: 10.1038/sj.mt.6000329

54. Gao X, Shen X, Dong X, Ran N, Han G, Cao L, et al. Peptide nucleic acid promotes systemic dystrophin expression and functional rescue in dystrophin-deficient mdx mice. *Mol Ther Nucleic Acids* 2015;4:e255. doi: 10.1038/mtna.2015.27

55. Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: Gene therapy approaches to sickle cell disease. *Blood* 2016;127(7):839-48. doi: 10.1182/blood-2015-09-618587

56. Rogers FA, Lin SS, Hegn DC, Krause DS, Glazer PM. Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. *Mol Ther* 2012;20(1):109-18. doi: 10.1038/mt.2011.163

57. Chin YJ, Glazer PM. Repair of DNA lesions associated with triplex-forming oligonucleotides. *Mol Carcinog* 2009;48(4):389-99. doi: 10.1002/mc.20501

58. McNeer NA, Schleifman EB, Cuthbert A, Brehm M, Jackson A, Cheng C, et al. Systemic delivery of triplex-forming PNA and donor DNA by
nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. *Gene Ther* 2013;20(6):658-69. doi: 10.1038/gt.2012.82

59. Chin JY, Kuan JY, Lonkar PS, Krause DS, Seidman MM, Peterson KR, et al. Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. *Proc Natl Acad Sci U S A* 2008;105(36):13514-9. doi: 10.1073/pnas.0711793105

60. Bahal R, McNeer NA, Quijano E, Liu Y, Sulkowski P, Turchick A, et al. In vivo correction of anaemia in β-thalassemic mice by ζPNA-mediated gene editing with nanoparticle delivery. *Nat Commun* 2016;7:13304. doi: 10.1038/ncomms13304

61. Ricciardi AS, Bahal R, McNeer NA, Quijano E, Bianchi AH, Luks VL, et al. In utero nanoparticle delivery for site-specific genome editing. *Nat Commun* 2018;9(1):2481. doi: 10.1038/s41467-018-04894-2

62. Rupainmoleo R, Slack FJ. Microrna therapeutics: Towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov* 2017;16(3):203-22. doi: 10.1038/nrd.2016.246

63. Marchelli R, Corradini R, Manicardi A, Sforza S, Tedeschi T, Fabbrini E, et al. Gene Modulation by Peptide Nucleic Acids (PNAs) Targeting microRNAs (miRs). In: You Y, editor. Targets in Gene Therapy. InTech; 2011. P. 29-46.

64. Fabani MM, Abreu-Goedger C, Williams D, Lyons PA, Torres AG, Smith KG, et al. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. *Nucleic Acids Res* 2010;38(13):4466-75. doi: 10.1093/nar/gkq160

65. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. *Nature* 2015;518(7537):107-10. doi: 10.1038/nature13905

66. Amato F, Tomaiuolo R, Borbone N, Elce A, Amato J, D’Errico S, et al. Design, synthesis and biochemical investigation, by in vitro Luciferase reporter system, of peptide nucleic acids as new inhibitors of mir-509-3p involved in the regulation of cystic fibrosis disease-gene expression. *MedChemComm* 2014;5(1):68-71. doi: 10.1039/C3MD00257H

67. Gupta A, Quijano E, Liu Y, Bahal R, Scanlon SE, Song E, et al. Anti-tumor activity of miniPEG-γ-modified PNAs to inhibit microRNA-210 for cancer therapy, *Mol Ther Nucleic Acids* 2017;9:111-9. doi: 10.1016/j.omtn.2017.09.001

68. Maekawa K, Azuma M, Okuno Y, Tsukamoto T, Nishiguchi K, Setsukinai K, et al. Antisense peptide nucleic acid-peptide conjugates for functional analyses of genes in Pseudomonas aeruginosa. *Bioorg Med Chem* 2015;23(22):7234-9. doi: 10.1016/j.bmc.2015.10.020

69. Kolevzon N, Nasereiddin A, Naik S, Yavin E, Dzikowski R. Use of peptide nucleic acids to manipulate gene expression in the malaria parasite Plasmodium falciparum. *PLoS One* 2014;9(9):e86802. doi: 10.1371/journal.pone.0086802

70. Amin-Avraham I, Pozner G, Eshar S, Fastman Y, Kolevzon N, Yavin E, et al. Antisense long noncoding RNAs regulate var gene activation in the malaria parasite Plasmodium falciparum. *Proc Natl Acad Sci U S A* 2015;112(9):E982-91. doi: 10.1073/pnas.1420855112

71. Mondhe M, Chessher A, Goh S, Good L, Stach JE. Species-selective killing of bacteria by antimicrobial peptide-PNAs. *PloS One* 2014;9(2):e89082. doi: 10.1371/journal.pone.0089082

72. Imamura Y, Tsuboi S, Sugiyama T, Kittaka A, Shin Y. A peptide nucleic acid to reduce type I collagen production by fibroblast cells. *Open J Med Chem* 2015;5(1):1-8. doi: 10.4236/ojmc.2015.51001

73. Alagpulinsa DA, Yacobo S, Ayyadevara S, Shmookler Reis RJ. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment. *Cancer Biol Ther* 2015;16(6):976-86. doi: 10.1080/15384047.2015.1040951

74. Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, et al. Antitumor activity of sustained N-myel reduction in rhabdomyosarcomas and transcriptional block by antigen therapy. *Cancer Res* 2012;72(3):796-807. doi: 10.1158/1078-0432.CCR-11-1981

75. Amato J, Stellato MI, Pizzo E, Petraccone L, Oliviero G, Borbone N, et al. PNA as a potential modulator of COL7A1 gene expression in dominant dystrophic epidermolysis bullosa: A physico-chemical study. *Mol BioSyst* 2013;9(12):3166-74. doi: 10.1039/c3mb07283a

76. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. *Proc Natl Acad Sci U S A* 2012;109(26):E1695-704. doi: 10.1073/pnas.1201516109

77. Brognara E, Fabbri E, Aimmi F, Manicardi A, Bianchi N, Finotti A, et al. Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. *Int J Oncol* 2012;41(6):2119-27. doi: 10.3892/ijo.2012.1632

78. Zeng Z, Han S, Hong W, Lang Y, Li F, Liu Y, et al. A Tat-conjugated Peptide Nucleic Acid Tat-PNA-DR Inhibits Hepatitis B Virus Replication In Vitro and In Vivo by Targeting LTR Direct Repeats of HBV RNA. *Mol Ther Nucleic Acids* 2016;5:e295. doi: 10.1038/mtna.2016.11

79. Bahal R, Quijano E, McNeer NA, Liu Y, Bhunia DC, Lopez-Giraldez F, et al. Single-stranded ζPNA for in vivo site-specific genome editing via Watson-Crick recognition. *Curr Gene Ther* 2014;14(5):331-42.

80. Nik-Ahd F, Bertoni C. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single-stranded oligodeoxynucleotides induces stable expression of...
dystrophin in a mouse model for duchenne muscular dystrophy. *Stem Cells* 2014;32(7):1817-30. doi: 10.1002/stem.1668
81. Ricciardi AS, Quijano E, Putman R, Saltzman WM, Glazer PM. Peptide nucleic acids as a tool for site-specific gene editing. *Molecules* 2018;23(3):632. doi: 10.3390/molecules23030632